Please ensure Javascript is enabled for purposes of website accessibility

Why PolarityTE Stock Tanked Today

By Brian Feroldi – Updated Apr 13, 2019 at 6:38PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares plunge after the company reports fourth-quarter results. Here's what investors need to know.

What happened

In response to the company's fourth-quarter results, shares of PolarityTE (PTE 10.52%), a commercial-stage biotech focused on regenerative medicine, fell as much as 24% in afternoon trading on Monday. The stock was down about 13% as of 3:47 p.m. EDT. 

So what

PolarityTE recently changed up its reporting period. The company decided to move its fiscal year-end from Oct. 31 to Dec. 31. That change means that this period includes data from only two months.

Here's how the company numbers shook out during the shortened period:

  • Revenue was $700,000. That fell well short of the $1.93 million that Wall Street was expecting. 
  • Net loss was $18.4 million, or $0.86 per share. That was better than the $1.06 loss that analysts had modeled.
  • Cash used in operations was $8 million.
  • Cash balance at year-end was $61.8 million.

It is worth pointing out that Wall Street's estimates appear to be based on the company's fiscal quarter ended on Jan. 31. That fact alone could explain why revenue and net loss were so much lower than expected.

Check out the latest earnings call transcripts for the companies we cover.

Man with head against wall in conference room

Image source: Getty Images.

Either way, traders didn't like the numbers that were reported, which is why shares are being sold off today.

Now what

PolarityTE has put its shareholders on a roller coaster ride in March. Just a few days ago, its share price shot higher after news broke that a Food and Drug Administration investigation was closed with a favorable outcome. All of those gains have evaporated in the wake of this disappointing earnings release. 

PolarityTE is scaling up its commercial team to drum up demand for its SkinTE product line. Market watchers are predicting that the company will hit $20 million in sales in 2019 and $86 million in 2020.

If it can hit those numbers, then the share price will probably start to head in the right direction. But this is a business with a questionable history, so my plan is to focus my attention elsewhere.

Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

PolarityTE, Inc. Stock Quote
PolarityTE, Inc.
$0.90 (10.52%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.